

DAFTAR PUSTAKA

1. Hossain MB, Haldar Neer AH. Chemotherapy. In: Qazi AS, Tariq K, editors. *Therapeutic Approaches in Cancer Treatment*. 2023. p. 49–58.
2. Ozyurt R, Celik N, Suleyman Z, Cagiran F, Kali Z, Gurkan N, et al. Fertility Protective Effect of Taxifolin in Cisplatin Induced Ovarian Damage. *Eur Rev Med Pharmacol Sci*. 2022;
3. Aldossary SA. Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin. *Biomedical and Pharmacology Journal*. 2019;12:7–15.
4. Tchounwou PB, Dasari S, Noubissi FK, Ray P, Kumar S. *Advances in Our Understanding of The Molecular Mechanisms of Action of Cisplatin in Cancer Therapy*. Journal of Experimental Pharmacology. Dove Medical Press Ltd; 2021.
5. Ranasinghe R, Mathai ML, Zulli A. *Cisplatin for Cancer Therapy and Overcoming Chemoresistance*. Heliyon. Elsevier Ltd; 2022.
6. Gandin V, Hoeschele JD, Margiotta N. Special Issue “Cisplatin in Cancer Therapy: Molecular Mechanisms of Action 3.0.” *International Journal of Molecular Sciences*. Multidisciplinary Digital Publishing Institute (MDPI); 2023.
7. Armstrong-Gordon E, Gnjjidic D, McLachlan AJ, Hosseini B, Grant A, Beale PJ, et al. Patterns of Platinum Drug Use in an Acute Care Setting: A Retrospective Study. *J Cancer Res Clin Oncol*. 2018;144:1561–8.
8. Elisya Y, Achmadi NK, Kurniawan D. Overview of Cytostatic Drug Prescribing for Inpatient Cancer Patients at RSUD Tarakan July-December 2021 Period. *SANITAS: Jurnal Teknologi dan Seni Kesehatan*. 2022;13:270–82.
9. Brown A, Kumar S, Tchounwou PB. Cisplatin-Based Chemotherapy of Human Cancers. *J Cancer Sci Ther*. 2019;11:97–103.
10. M.Gold J, Raja A. *Cisplatin*. StatPearls; 2023.
11. Ciplak B, Turmus EG, Kara O, Daglioglu G, Altindag MM, Simsek Y, et al. Does Resveratrol Reduce Cisplatin-Induced Ovarian Damage? *Rev Assoc Med Bras*. 2023;69.
12. Spears N, Lopes F, Stefansdottir A, Rossi V, De Felici M, Anderson RA, et al. Ovarian Damage from Chemotherapy and Current Approaches to its Protection. *Hum Reprod Update*. 2019;25:673–93.
13. Maneschi F, Benedetti-Panici P, Scambia G, Salerno MG, Agostino D, Mancuso S. Menstrual and Hormone Patterns in Woman Treated with High-Dose Cisplatin and Bleomycin. *Gynecol Oncol*. 1994;
14. Sonigo C, Beau I, Binart N, Grynberg M. The Impact of Chemotherapy on The Ovaries: Molecular Aspects and The Prevention of Ovarian Damage. *International Journal of Molecular Sciences*. MDPI AG; 2019.
15. Mathis KM, Sturgeon KM, Winkels RM, Wiskemann J, Williams NI, Schmitz K. Exercise and Chemotherapy Induced Amenorrhea. *Med Hypotheses*. 2018;116:49–53.
16. Gaffan J, Holden L, Newlands ES, Short D, Fuller S, Begent RHJ, et al. Infertility Rates Following POMB/ACE Chemotherapy for Male and Female Germ Cell Tumours - A Retrospective Long Term Follow Up Study. *Br J Cancer*. 2003;89:1849–54.

17. Zhou B, Kwan B, Desai MJ, Nalawade V, Henk J, Viravalli N, et al. Association of Platinum Based Chemotherapy with Live Birth and Infertility in Female Survivors of Adolescent and Young Adult Cancer. *Fertil Steril*. 2024;121:1020–30.
18. Anggraeni Palang Tukan L, Herawati F, Kirtishanti A, Yulia R, Kartika Octavia S. Studi Penggunaan Kemoterapi pada Pasien Kanker Serviks di RSPAL Dr. Ramelan Surabaya. *Jurnal Sains dan Kesehatan (J Sains Kes)* 2024. 6:353.
19. Novitasari C, Attamimi A, Pradjatmo H. Perbandingan Angka Ketahanan Hidup Penderita Kanker Ovarium yang Mendapat Terapi Regimen Kemoterapi Paclitaxel-Carboplatin dan Vyclophosphamide-Adriamycin-Cisplatin di RSUP Dr. Sardjito: Studi retrospektif Januari 2014-Desember 2018. *Jurnal Kesehatan Reproduksi*. 2020;7:73–80.
20. Haryani S. Evaluasi Penggunaan Obat Kemoterapi pada Pasien Kanker Payudara di RSUP Fatmawati Periode Februari 2021. *Jurnal Farmasi Klinik-Base Practice*. 2022;1:50–60.
21. Letourneau JM, Smith JF, Ebbel EE, Craig A, Katz PP, Cedars MI, et al. Racial, Socioeconomic, and Demographic Disparities in Access to Fertility Preservation in Young Women Diagnosed with Cancer. *Cancer*. 2012;118:4579–88.
22. Ruddy KJ, Gelber SI, Tamimi RM, Ginsburg ES, Schapira L, Come SE, et al. Prospective Study of Fertility Concerns and Preservation Strategies in Young Women with Breast Cancer. *Journal of Clinical Oncology*. 2014;32:1151–6.
23. Borovskaya TG, Goldberg VE, Fomina TI, Pakhomova A V, Kseneva SI, Poluektova ME, et al. Morphological and Functional State of Rat Ovaries in Early and Late Periods After Administration of Platinum Cytostatics. Vol. 137, *Bulletin of Experimental Biology and Medicine*. 2004.
24. Sait Yucebilgin M, Cosan Terek M, Ozsaran A, Akercan F, Zekioglu O, Isik E, et al. Effect of Chemotherapy on Primordial Follicular Reserve of Rat: An Animal Model of Premature Ovarian Failure and Infertility. Vol. 44, *Australian and New Zealand Journal of Obstetrics and Gynaecology*. 2004.
25. Eldani M, Luan Y, Xu PC, Bargar T, Kim SY. Continuous Treatment with Cisplatin Induces the Oocyte Death of Primordial Follicles Without Activation. *FASEB Journal*. 2020;34.
26. Al-Shahat A, Hulail MAE, Soliman NMM, Khamis T, Fericean LM, Arisha AH, et al. Melatonin Mitigates Cisplatin-Induced Ovarian Dysfunction via Altering Steroidogenesis, Inflammation, Apoptosis, Oxidative Stress, and PTEN/PI3K/Akt/mTOR/AMPK Signaling Pathway in Female Rats. *Pharmaceutics*. 2022;14.
27. Arni K, Dewi B, Purwanto W. Introduction of Histopathology. In: *Molecular Histopathology and Cytopathology*. IntechOpen; 2023. p. 1–12.
28. P. Eroschenko V. diFiore's Atlas of Histology with Functional Correlations. 12th ed. Lippincott Williams & Wilkins; 2013.
29. Moore KL, Dalley AF. Anatomi Berorientasi Klinis. 5th ed. Vol. 1. Jakarta: Erlangga; 2013.
30. Sloane E. Anatomi dan Fisiologi untuk Pemula. Jakarta: Buku Kedokteran EGC; 2004.

31. Sherwood L. Fisiologi Manusia dari Sel ke Sistem . 8th ed. Jakarta: Buku Kedokteran ECG; 2014.
32. Gartner LP, Hiatt JL. Atlas Berwarna Histologi. 5th ed. Susilowati RW, editor. Tangerang : Binarupa Aksara; 2012.
33. E. Hall J. Guyton and Hall Textbook of Medical Physiology. 12th ed. Singapore: Elsevier; 2014.
34. Hardjono S, Siswandono, Diyah NW. Obat Antikanker. Surabaya: Airlangga University Press; 2016.
35. Andayani N, Julisafrida L. Peranan Immunoterapi Pada Kanker Paru. Jurnal Kedokteran Syiah Kuala. 2020;20.
36. Putra A. Basic Molecular Stem Cell. Kusnadi Y, Soebandrio A, editors. Semarang: Unisulla Press; 2019.
37. Hussein A, Hussein K, Babkair H, Badawy M. Anti-Cancer Medicine (Classification And Mechanism Of Action). Egypt Dent J. 2024;70.
38. Gabora K, Piciu A, Bădulescu IC, Larg MI, Stoian IA, Piciu D. Current Evidence on Thyroid Related Adverse Events in Patients Treated with Protein Tyrosine Kinase Inhibitors. Drug Metabolism Reviews. Taylor and Francis Ltd; 2019.
39. Meirrow D, Dor J, Kaufman B, Shrim A, Rabinovici J, Schiff E, et al. Cortical Fibrosis and Blood Vessels Damage in Human Ovaries Exposed to Chemotherapy. Potential Mechanisms of Ovarian Injury. Human Reproduction. 2007;22.
40. Morcos MA. Histological and Immunohistochemical Study on The Protective Effects of Cetrorelix Against Chemotherapy Induced Ovarian Damage. Egyptian Journal of Histology. 2012;35.
41. Afifi NM, Reyad ON. Role of Mesenchymal Stem Cell Therapy in Restoring Ovarian Function in A Rat Model of Chemotherapy-Induced Ovarian Failure: A Histological and Immunohistochemical Study. Egyptian Journal of Histology. 2013;36:126.
42. Rusdi NK, Sari EN, Wulandari N. Ketepatan Obat, Dosis, dan Potensi Interaksi Obat pada Pasien Kanker Paru di Rumah Sakit X Jawa Barat Periode 2019-2021. Jurnal Sains dan Kesehatan. 2023;5:323.
43. L.Lemke T, Williams DA, F.Roche V, Zito SW. Foye's Principles of Medicinal Chemistry. Seventh. 2013.
44. Miatmoko A. Physical Characterization and Biodistribution of Cisplatin Loaded in Surfactant Modified Hybrid Nanoparticles Using Polyethylene Oxide-B-Polymethacrylic Acid. Adv Pharm Bull. 2021;11.
45. Shargel L, B.C.Yu A. Applied Biopharmaceutics and Pharmacokinetics. Seventh. 2016.
46. Kopacz-Bednarska A, Król T. Cisplatin Properties and Clinical Application. Oncology in Clinical Practice. Via Medica; 2022.
47. Khalidah AR. Literature Review: Mekanisme Resistensi Kemoterapi Berbasis Platinum Literature Review: Mechanism Resistance of Platinum-Based Chemotherapy. Jurnal Kesehatan. 2020;11.
48. Petrović M, Todorović D. Biochemical and Molecular Mechanisms of Action of Cisplatin in Cancer Cells. Medicine and Biology. 2016;18.

49. Dasari S, Njiki S, Mbemi A, Yedjou CG, Tchounwou PB. Pharmacological Effects of Cisplatin Combination with Natural Products in Cancer Chemotherapy. *Int J Mol Sci.* 2022;23:1–25.
50. Zoń A, Bednarek I. Cisplatin in Ovarian Cancer Treatment Known Limitations in Therapy Force New Solutions. *International Journal of Molecular Sciences.* Multidisciplinary Digital Publishing Institute (MDPI); 2023.
51. Djordjević M, Ilić J, Stojanovic NM. Cisplatin An Overview of Its Efficiency and Toxicity. *Facta Universitatis, Series: Medicine and Biology.* 2023;
52. Qi L, Luo Q, Zhang Y, Jia F, Zhao Y, Wang F. Advances in Toxicological Research of the Anticancer Drug Cisplatin. *Chemical Research in Toxicology.* American Chemical Society; 2019.
53. Alesi LR, Nguyen QN, Stringer JM, Winship AL, Hutt KJ. The Future of Fertility Preservation for Women Treated with Chemotherapy. Vol. 4, *Reproduction and Fertility.* BioScientifica Ltd.; 2023.
54. Monniaux D. Factors Influencing Establishment of The Ovarian Reserve and Their Effects on Fertility. *Anim Reprod.* 2018;15:635–47.
55. Liu T, Huang Y, Lin H. Estrogen Disorders: Interpreting The Abnormal Regulation of Aromatase in Granulosa Cells (Review). Vol. 47, *International Journal of Molecular Medicine.* Spandidos Publications; 2021.
56. Chigbu UE, Atiku SO, Du Plessis CC. The Science of Literature Reviews: Searching, Identifying, Selecting, and Synthesising. *Publications.* 2023;11.
57. Grant MJ, Booth A. A Typology of Reviews: An Analysis of 14 Review Types and Associated Methodologies. *Health Information and Libraries Journal.* 2009.
58. Heryana A. Jenis Jenis Studi Literature Review. 2021;
59. Brennan ML, Arlt SP, Belshaw Z, Buckley L, Corah L, Doit H, et al. Critically Appraised Topics (CATs) in Veterinary Medicine: Applying Evidence in Clinical Practice. *Frontiers in Veterinary Science.* Frontiers Media S.A.; 2020.
60. Parasuraman S. Toxicological screening. *J Pharmacol Pharmacother.* 2011;2:74–9.
61. V Turner P, Brabb T, Pekow C, Ann Vasbinder M. Administration of Substances to Laboratory Animals : Routes of Administration and Factors to Consider. *Journal of the American Association for Laboratory Animal Science.* 2011;
62. Dai F, Wang R, Deng Z, Yang D, Wang L, Wu M, et al. Comparison of the different animal modeling and therapy methods of premature ovarian failure in animal model. Vol. 14, *Stem Cell Research and Therapy.* BioMed Central Ltd; 2023.
63. Perše M. Cisplatin Mouse Models: Treatment, Toxicity and Translatability. *Biomedicines.* 2021;
64. Waheed IN, Abdullah A, Ameen M, Jasim J, Ali BN. Histopathological Study Of The Effect Of Cisplatin On The Ovaries Of Females Albino Mice. *Journal of University of Zakho.* 2014;
65. Chinedu E, Arome D, Solomon Ameh F, Luka Jacob D. An Approach to Acute, Subacute, Subchronic, and Chronic Toxicity Assessment in Animal Models. *Toxicol Int.* 2015;22.

66. Anwar R, Fertilitas S, Reproduksi DE, Obstetri B, Ginekologi D. *Morfologi dan Fungsi Ovarium*. 2005.
67. Qn N, Sh L, Jk F, Hickey M, Kj H, Hutt K. Cisplatin and Cyclophosphamide Induced Primordial Follicle Depletion is Caused by Direct Damage to Oocytes. *Mol Hum Reprod*. 2019;
68. Barbosa LMR, Barberino RS, Gouveia BB, Menezes VG, Palheta RC, Matos MHT. Protective Effect of Kaempferol Against Cisplatin Induced Acute Ovarian Damage in A Mouse Model. *Arq Bras Med Vet Zootec*. 2022;74.
69. Gouveia BB, Barberino R de S, dos Santos Silva RL, Lins TLBG, da Silva Guimarães V, do Monte APO, et al. Involvement of PTEN and FOXO3a Proteins in the Protective Activity of Protocatechuic Acid Against Cisplatin Induced Ovarian Toxicity in Mice. *Reproductive Sciences*. 2020;
70. Lins TLBG, Gouveia BB, Barberino RS, Silva RLS, Monte APO, Pinto JGC, et al. Rutin Prevents Cisplatin Induced Ovarian Damage Via Antioxidant Activity and Regulation of PTEN and FOXO3a Phosphorylation in Mouse Model. *Reproductive Toxicology*. 2020;
71. Zhang S, Liu Q, Chang M, Pan Y, Yahaya BH, Liu Y, et al. Chemotherapy Impairs Ovarian Function Through Excessive ROS-Induced Ferroptosis. *Cell Death Dis*. 2023;14.
72. Erbaş O, Akman L, Yavaşoğlu A, Terek MC, Akman T, Taskiran D. Oxytocin Improves Follicular Reserve in A Cisplatin Induced Gonadotoxicity Model in Rats. *Biomed Res Int*. 2014;
73. Soyman Z, Uzun H, Bayindir N, Esrefoglu M, Boran B. Can Ebselen Prevent Cisplatin Induced Ovarian Damage? *Gynecologic Endocrinology and Reproductive Medicine*. 2018;
74. Dinc K, Ozyurt R, Coban TA, Yazici GN, Suleyman Z, Yavuzer B, et al. The Effect of Carvacrol on The Proinflammatory Cytokines, Histology, and Fertility Outcome of Cisplatin Related Ovarian Change in A Rat Model. *Taiwan J Obstet Gynecol*. 2022;
75. Şahin HÖ, Duran MN, Silan F, Silan E, Sıddıkoglu D, Kılınç N. Investigation of TAp63 Gene Expression and Follicle Count Using Melatonin in Cisplatin Induced Ovarian Toxicity. *Int J Res Med Sci*. 2021;9.
76. Atli M, Engin-Ustun Y, Tokmak A, Caydere M, Hucumenoglu S, Topcuoglu C. Dose Dependent Effect of Resveratrol in Preventing Cisplatin Induced Ovarian Damage in Rats: An Experimental Study. *Reprod Biol*. 2017;
77. Ozdamar S, Taskin MI, Onder GO, Kaymak E, Baran M, Yay A. Progesterone Decreases the Extent of Ovarian Damage Caused by Cisplatin in An Experimental Rat Model. *Advances in Clinical and Experimental Medicine*. 2018;28.
78. Kulhan NG, Kulhan M, Turkler C, Ata N, Kiremitli T, Kiremitli S, et al. Effect of Lycopene on Oxidative Ovarian Damage Induced by Cisplatin in Rats. *Gen Physiol Biophys*. 2019;
79. Taskin MI, Yay A, Adali E, Balcioglu E, Inceboz U. Protective Effects of Sildenafil Citrate Administration on Cisplatin Induced Ovarian Damage in Rats. *Gynecological Endocrinology*. 2014;
80. Said RS, Mantawy EM, El-Demerdash E. Mechanistic Perspective of Protective Effects of Resveratrol Against Cisplatin Induced Ovarian Injury

- in Rats: Emphasis on Anti Inflammatory and Anti Apoptotic Effects. *Naunyn Schmiedebergs Arch Pharmacol*. 2019;
81. kaygusuzoglu E, Caglayan C, Kandemir FM, Yıldırım S, Kucukler S, Kılınç MA, et al. Zingerone Ameliorates Cisplatin Induced Ovarian and Uterine Toxicity Via Suppression of Sex Hormone Imbalances, Oxidative Stress, Inflammation and Apoptosis in Female Wistar Rats. *Biomedicine and Pharmacotherapy*. 2018;
 82. Ibrahim MA, Albahlol IA, Wani FA, Abd-Eltawab Tammam A, Kelleni MT, Sayeed MU, et al. Resveratrol Protects Against Cisplatin Induced Ovarian and Uterine Toxicity in Female Rats by Attenuating Oxidative Stress, Inflammation and Apoptosis. *Chem Biol Interact*. 2021;
 83. Pandir D, Kara O, Kara M. Protective Effect of Bilberry (*Vaccinium myrtillus* L.) on Cisplatin Induced Ovarian Damage in Rat. *Cytotechnology*. 2014;
 84. DoÓan GO, ErbaÓ O. Exenatide Improves Cisplatin Induced Ovarian Damage Through NLRP3, Nrf-2, and TLR4 Pathways. *Cir Cir*. 2023;
 85. Guo Y, Xue L, Tang W, Xiong J, Chen D, Dai Y, et al. Ovarian Microenvironment: Challenges and Opportunities in Protecting Against Chemotherapy-Associated Ovarian Damage. *Human Reproduction Update*. Oxford University Press; 2024.
 86. Bedoschi GM, Navarro PA, Oktay KH. Novel Insights Into The Pathophysiology of Chemotherapy-Induced Damage to The Ovary. *Panminerva Med*. 2019;
 87. Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: Mechanisms and clinical impact. *Future Oncology*. 2016;12:2333–44.
 88. Dabbish E, Scoditti S, Shehata MNI, Ritacco I, Ibrahim MAA, Shoeib T, et al. Insights on cyclophosphamide metabolism and anticancer mechanism of action: A computational study. *J Comput Chem*. 2024;45:663–70.
 89. Yang W, Ma Y, Jin J, Ren P, Zhou H, Xu S, et al. Cyclophosphamide Exposure Causes Long Term Detrimental Effect of Oocytes Developmental Competence Through Affecting the Epigenetic Modification and Maternal Factors Transcription During Oocyte Growth. *Front Cell Dev Biol*. 2021;9.
 90. Yu Y, Guo Y, Zhu J, Shen R, Tang J. Chemotherapy Drug Combinations Induced Maternal Ovarian Damage and Long Term Effect on Fetal Reproductive System in Mice. *European Journal of Pharmaceutical Sciences*. 2024;
 91. Chang EM, Lim E, Yoon S, Jeong K, Bae S, Lee DR, et al. Cisplatin Induces Overactivation of The Dormant Primordial Follicle Through PTEN/AKT/FOXO3 α Pathway which Leads to Loss of Ovarian Reserve in Mice. *PLoS One*. 2015;
 92. Turkler C, Kiremitli T, Onat T, Yildirim E, Yazici GN, Mammadov R, et al. Can Pycnogenol Prevent Cisplatin Induced Damage in Uterus and Ovaries? *Archives of Medical Science*. 2022;18:1371.
 93. Osman AMM, Alqahtani AA, Damanhour ZA, Al-Harthy SE, ElShal MF, Ramadan WS, et al. Dimethylsulfoxide Exacerbates Cisplatin Induced Cytotoxicity in Ehrlich Ascites Carcinoma Cells. *Cancer Cell Int*. 2015;

94. Kim SY, Cordeiro MH, Serna VA, Ebbert K, Butler LM, Sinha S, et al. Rescue of platinum-damaged oocytes from programmed cell death through inactivation of the p53 family signaling network. *Cell Death Differ.* 2013;20:987–97.

